Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery

NCT01276496 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

13

Enrollment

NIH

Sponsor class

Conditions

Adult Solid Neoplasm
Estrogen Receptor Negative
HER2/Neu Negative
Male Breast Carcinoma
Progesterone Receptor Negative
Recurrent Breast Carcinoma
Stage IIIB Breast Cancer
Stage IIIC Breast Cancer
Stage IV Breast Cancer
Triple-Negative Breast Carcinoma

Interventions

DRUG: Cilengitide
OTHER: Laboratory Biomarker Analysis
DRUG: Paclitaxel
OTHER: Pharmacological Study

Sponsor

National Cancer Institute (NCI)